A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.
- DOI
- 10.1007/s00262-026-04333-y
- Published
- 2026 Apr 11
- Container
- Cancer immunology, immunotherapy : CII
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00262-026-04333-y,
title = {A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.},
author = {Konopleva M and Bhatt VR and Mantzaris I and Maiti A and Gundabolu K and Schafer J and Jensen K and Saleem R and Li Y and Drewniak A and Bay P and Huh W and Yildirim O and Abbadessa G and Cooley S and Daver N},
year = {2026},
journal = {Cancer immunology, immunotherapy : CII},
doi = {10.1007/s00262-026-04333-y},
url = {https://doi.org/10.1007/s00262-026-04333-y}
}RIS
TY - JOUR TI - A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia. AU - Konopleva M AU - Bhatt VR AU - Mantzaris I AU - Maiti A AU - Gundabolu K AU - Schafer J AU - Jensen K AU - Saleem R AU - Li Y AU - Drewniak A AU - Bay P AU - Huh W AU - Yildirim O AU - Abbadessa G AU - Cooley S AU - Daver N PY - 2026 JO - Cancer immunology, immunotherapy : CII DO - 10.1007/s00262-026-04333-y UR - https://doi.org/10.1007/s00262-026-04333-y ER -
APA
M, K., VR, B., I, M., A, M., K, G., J, S., K, J., R, S., Y, L., A, D., P, B., W, H., O, Y., G, A., S, C., & N, D. (2026). A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-026-04333-y
Source records
- pubmed · retrieved 2026-09-27T06:25:21.085Z